- News & Features
A support group is a group of people with common concerns or experiences who provide advice, comfort and encouragement to...
Study finds that most RA, PsA, and AS patients can switch from infliximab (Remicade) to biosimilar CT-P13 without losing safety or effectiveness.
Over 11,500 patients have enrolled in ArthritisPower, our patient-led, patient-centered research registry for joint, bone, and inflammatory skin conditions.
Arthritis patients with resolved hepatitis B infection, who received disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, were unlikely to have the hepatitis B resurface.
Gout may be associated with greater risk of severe knee osteoarthritis, which in turn requires total knee replacement surgery.
New research demonstrates that twins of lupus patients are at an increased risk of also contracting lupus or another autoimmune disease.
Fibromyalgia, a disorder that affects and amplifies the ways the brain feels pain, can “mask” underlying spondyloarthritis.
Even if each new study is correct, “it may only be one star in the sky.”
We are proud to announce we’ve hit an important milestone: The ArthritisPower community has donated over 50,000 patient reported outcomes to research!
Researchers at University of California have created and are testing artificial tissue, which appears to be up to six times as strong as natural cartilage.
Abatacept treatment of PsA in this phase III study showed beneficial trends overall in musculoskeletal manifestations and was well tolerated.